@inproceedings{inproceedings, title  = {{Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer}},

 publisher = {{American Association for Cancer Research (AACR)}},

 url = {{https://doi.org/10.1158/1538-7445.sabcs17-gs2-07 }},

 year = {{2018}},

 month = {{2}},

 author = {{Schmid P and Zaiss M and Harper-Wynne C and Ferreira M and Dubey S and Chan S and Makris A and Nemsadze G and Brunt AM and Kuemmel S and Ruiz Cabrero I et al}},

 doi = {{10.1158/1538-7445.sabcs17-gs2-07}},

 volume = {{78}},

 journal = {{Cancer Research}},

 issue = {{4_Supplement}},

 note = {{Accessed on 2025/11/03}}}